• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Kendle Looking to Grow Phase I Business

Kendle Looking to Grow Phase I Business

January 21, 2008
CenterWatch Staff

Cincinnati-based CRO Kendle is expanding its phase I business with the appointment of Philip Davies, a 20-year industry veteran in early stage research, and made another key hire to grow its Asia-Pacific operations.

The company stated that Davies will provide the leadership needed to grow its phase I units, which include a clinical pharmacology unit in The Netherlands and a bioequivalence facility in West Virginia. Kendle said Davies will focus on expanding its capabilities worldwide.

Prior to the appointment, Davies had roles within Kendle’s pharmacology business in Germany and the UK. Before joining Kendle, he spent six years with Eli Lilly in its pharmacology operations. Most recently, Davies was director of global exploratory and program phase medical operations. Davies, as vice-president of phase I, will report directly to Kendle’s chief executive officer, Candace Kendle, PharmD.

“Phase I is a rapidly growing area of opportunity and is an integral part of Kendle’s business plan, with the market to grow between 13.4 and 16% annually through 2010,” said Kendle.

Kendle also hired Ross Horsburgh, M.D. as vice president of global clinical development for the Asia Pacific region. Prior to joining Kendle, Horsburg was regional medical director for AstraZeneca’s Asia Pacific region. He will be based in Singapore and report to Martha Feller, senior vice president of global clinical development for phase I through III operations.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing